AR043772A1 - Formulaciones que comprenden un ingrediente activo y cacao en polvo y su uso - Google Patents

Formulaciones que comprenden un ingrediente activo y cacao en polvo y su uso

Info

Publication number
AR043772A1
AR043772A1 ARP040100981A ARP040100981A AR043772A1 AR 043772 A1 AR043772 A1 AR 043772A1 AR P040100981 A ARP040100981 A AR P040100981A AR P040100981 A ARP040100981 A AR P040100981A AR 043772 A1 AR043772 A1 AR 043772A1
Authority
AR
Argentina
Prior art keywords
ifa
agent
drugs
cocoa powder
formulation according
Prior art date
Application number
ARP040100981A
Other languages
English (en)
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of AR043772A1 publication Critical patent/AR043772A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)

Abstract

Reivindicación 1: Una formulación farmacéutica administrada por vía oral caracterizada porque comprende uno o más ingredientes farmacéuticos activos (IFA), que opcionalmente comprende sus sales, complejos, profármacos y metabolitos, que comprende cacao en polvo y porque él, uno o más, IFA se eligen(n) entre IFA adecuados para absorción oral. Reivindicación 2: Una formulación de acuerdo con la reivindicación 1, caracterizada porque él, uno o más, ingredientes farmacéuticos activos (IFA) se selecciona(n) de: los agentes antiinflamatorios diclofenaco, ketorolac, indometacina, tornoxicam, piroxicam, ketoprofeno, celecoxib y roficoxib; los relajantes musculares orfenadrina y baclofeno; los fármacos que afectan a la mineralización ósea ácido alendrónico y ácido risedrónico; los analgésicos propoxifeno, buprenorfina, kerobenidona, hidromorfona, tramadol y morfina; las preparaciones antimigranosas dihidroergotamina, ergotamina, eletriptan, naratriptan, rizatriptan, sumatriptan y zolmitriptan; los fármacos contra el Parkinson, pramipexol, ropinorol y selegilina; los ansiolíticos alprazolam, diazepam, lorazepam y oxazepam; los hipnóticos flunitrazepam, midazolam, nitrazepam, triazolam, zaleplona, zopiclona, zolpiderm, clometiazol y propiomazina; el psicoestimulante cafeína; los fármacos contra las toxicomanías bupropiona, lobelina, naltrexona y metadona; los remedios contra úlcera gástrica famotidina y ranitidina; el antiespasmódico hiosciamina, los antieméticos metoclopramida, ondansetron, escopolamina, hioscina, perfenacina, procloperazina, meclizina y haloperidol; el agente antidiabético rosiglitazona; los agentes cardiovasculares etilefrina, trinitrato de glicerilo, dinitrato de isosorbida y mononitrato de isosorbida; el agente antihipertensor hidralazina; los diuréticos furosemida y amilorida; los agentes bloqueantes de los receptores beta propanolol y timolol; el bloqueante de canal de calcio amlodipina; los inhibidores de ACE captopril, lisinopril y fosinopril; el agente reductor de lípidos en suero simvastatina; el agente antisoriásico acitretina; el antiasmático terbutalina; los descongestivos pseudoefedrina fenilefrina; el fármaco antidiarreico loperamida; los antitusivos dextrometorfano, codeína noscapina; y las antihistaminas clemastina, clorfeniramina, ciproheptadina, loratadina, acrivastina, difenhidramina, cetirizina, doxilamina y dimenhidrinato. Reivindicación 18: Uso de una formulación de acuerdo con cualquiera de las reivindicaciones precedentes para la fabricación de un medicamento de utilidad caracterizado porque es para el tratamiento médico de un ser humano o de un animal.
ARP040100981A 2003-03-26 2004-03-24 Formulaciones que comprenden un ingrediente activo y cacao en polvo y su uso AR043772A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0300831A SE0300831D0 (sv) 2003-03-26 2003-03-26 New formulations and use therof

Publications (1)

Publication Number Publication Date
AR043772A1 true AR043772A1 (es) 2005-08-10

Family

ID=20290786

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100981A AR043772A1 (es) 2003-03-26 2004-03-24 Formulaciones que comprenden un ingrediente activo y cacao en polvo y su uso

Country Status (13)

Country Link
EP (1) EP1605921A1 (es)
JP (2) JP2006521348A (es)
CN (1) CN1764440A (es)
AR (1) AR043772A1 (es)
AU (1) AU2004224557B2 (es)
BR (1) BRPI0408655A (es)
CA (1) CA2519155A1 (es)
CL (1) CL2004000564A1 (es)
MX (1) MXPA05010196A (es)
SE (1) SE0300831D0 (es)
TW (1) TW200503782A (es)
WO (1) WO2004084865A1 (es)
ZA (1) ZA200507719B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
IL149352A0 (en) 1999-10-29 2002-11-10 Euro Celtique Sa Controlled release hydrocodone formulations
EP2295042A1 (en) 2000-10-30 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
JP5558712B2 (ja) * 2005-08-02 2014-07-23 ドロサファーム アクチェンゲゼルシャフト インドメタシン及び／又はアセメタシンを含む医薬組成物
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
TWI473572B (zh) 2007-06-13 2015-02-21 大塚製藥股份有限公司 An extract containing equol (EQUOL), a method for producing the same, an equol extraction method and an equol-containing food
CN101439053A (zh) * 2007-11-22 2009-05-27 何煜 一种中药口腔速释制剂及其制造方法
CN101444273B (zh) * 2007-11-22 2013-04-24 何煜 一种保健品口腔速释制剂及其制造方法
WO2009070978A1 (fr) * 2007-11-22 2009-06-11 Yu He Libération rapide dans la cavité buccale des produits de santé et procédé de préparation associé
AU2010262738A1 (en) * 2009-05-20 2011-10-13 Lingual Consegna Pty Ltd Buccal and/or sublingual therapeutic formulation
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
MX2012012991A (es) 2010-05-11 2012-11-30 Cima Labs Inc Formas de dosificacion oral de liberacion prolongada resistentes al alcohol y que contienen metoprolol.
WO2014135967A1 (en) 2013-03-06 2014-09-12 Capsugel Belgium Nv Curcumin solid lipid particles and methods for their preparation and use
CN103583781B (zh) * 2013-11-01 2015-11-25 阳波 咖啡味甲硝唑口香糖
EP3154529B1 (en) * 2014-06-10 2020-07-08 Capsugel Belgium NV Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use
US11324699B2 (en) 2014-12-04 2022-05-10 Capsugel Belgium Nv Lipid multiparticulate formulations
JP6334482B2 (ja) * 2015-08-28 2018-05-30 中野Ｂｃ株式会社 固形剤とその製造方法
AU2016367036B2 (en) * 2015-12-09 2019-04-18 Poviva Corp. Methods for formulating orally ingestible compositions comprising lipophilic active agents
CN108430233A (zh) * 2015-12-09 2018-08-21 波维瓦茶业有限责任公司 包含亲脂性活性剂的稳定的即饮型饮料组合物
AU2017361129B2 (en) * 2016-11-18 2023-11-09 Telethon Kids Institute Taste masking product
BR112020017468A2 (pt) * 2018-03-01 2020-12-22 Lts Lohmann Therapie-Systeme Ag Forma de dosagem oral com cacau livre de teobromina
CN109053718B (zh) * 2018-08-09 2022-06-03 天津理工大学 一种罗格列酮糖精盐及其制备方法
CN111729087A (zh) * 2020-07-24 2020-10-02 成都大学 一种选择性β2受体激动剂的脂质修饰物及其制备方法与用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB785574A (en) * 1955-03-29 1957-10-30 Pfizer & Co C Pharmaceutical compositions containing tetracycline antibiotics
GB918955A (en) * 1960-05-19 1963-02-20 Thomae Gmbh Dr K Pharmaceutical laxative compositions comprising 4,4-dihydroxy-2-amino triphenylmethane
FR2717387B1 (fr) * 1994-03-17 1996-10-18 Hi Pharmtech Procédé de fabrication de comprimés à croquer à base de troxérutine, de carbonate de calcium, de phosphate de calcium, d'aspartate d'arginine, de glutamate d'arginine d'amoxicilline.
SE9803986D0 (sv) * 1998-11-23 1998-11-23 Pharmacia & Upjohn Ab New compositions
JP2001106641A (ja) * 1999-10-06 2001-04-17 Tendou Seiyaku Kk 口内薬
JP2001114668A (ja) * 1999-10-13 2001-04-24 Meiji Seika Kaisha Ltd チョコレート剤
JP2002193839A (ja) * 2000-12-27 2002-07-10 Meiji Seika Kaisha Ltd ココア製剤
US20020172732A1 (en) * 2001-03-21 2002-11-21 Wies Ter Laak Composition comprising cocoa
SE0103211D0 (sv) * 2001-09-27 2001-09-27 Pharmacia Ab New formulations and use thereof

Also Published As

Publication number Publication date
CA2519155A1 (en) 2004-10-07
WO2004084865A1 (en) 2004-10-07
MXPA05010196A (es) 2005-11-08
TW200503782A (en) 2005-02-01
AU2004224557A1 (en) 2004-10-07
SE0300831D0 (sv) 2003-03-26
BRPI0408655A (pt) 2006-03-28
JP2006521348A (ja) 2006-09-21
ZA200507719B (en) 2007-09-26
CN1764440A (zh) 2006-04-26
EP1605921A1 (en) 2005-12-21
JP2011079841A (ja) 2011-04-21
CL2004000564A1 (es) 2005-02-04
AU2004224557B2 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
AR043772A1 (es) Formulaciones que comprenden un ingrediente activo y cacao en polvo y su uso
KR101595139B1 (ko) 치은 웨이퍼
US6626669B2 (en) Oral therapeutic delivery appliance
ES2232886T3 (es) Formulaciones de dosificacion de cesion controlada en un momento especifico y metodo para preparar las mismas.
ES2328115T3 (es) Preparado farmaceutico mucoadhesivo desintegrable para la administracion de sustancia activa en medicina veterinaria y humana.
ES2319968T3 (es) Composiciones de hierbas para el tratamiento de lesiones de la mucosa.
WO2005046640A3 (en) Multi-site drug delivery platform
Rathbone et al. Overview of oral mucosal delivery
JP2009518374A (ja) 活性薬剤、特にジクロフェナクの経皮投与
HUP0203733A2 (en) Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy
JP2008505977A (ja) 治療薬及び／又は健康増進薬の膣送達用被覆経膣デバイス
WO2003047519A3 (en) 'compressed annular tablet with molded triturate tablet for oral and intraoral'
DE60133319D1 (de) Mehrfach beschichete pharmazeutische dosierungsform
CN108066305A (zh) 改善口崩片硬度和崩解的方法和定位释放口腔崩解片
IT1315252B1 (it) Compresse gastroresistenti ad uso alimentare o dietetico ottenutemediante grassi miscelati alla massa
Thulluru et al. Sublingual tablets-an updated review
EP3068450B1 (de) Zahnprothese als darreichungsform zur behandlung chronischer erkrankungen
KR101949608B1 (ko) 발뒤꿈치 보습용 패드
RU2668690C2 (ru) Дентальная накладка
US20100172956A1 (en) Dissolving strip for oral mucosa as a systemic drug delivery route
JP2006232770A (ja) 外用組成物及びそれを含有する外用剤
WO2001060278A2 (en) Oral therapeutic delivery appliance
Shaikh et al. A REVIEW ON BUCOADHESIVE DRUG DELIVERY SYSTEM
ZO et al. An Overview on Buccal Drug Delivery System
Chotaliya OVERVIEW OF SUBLINGUAL TABLETS.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal